Sign InBreakout Stocks of Week 23 @ FRA
NASDAQ was up last week (week 22) by 2.40% ending at 26,976.35 points after gaining 632.38 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are RWE Aktiengesellschaft FRA:RWE. This stock has had a buy signal since May 29, 2026 when the price was 54.56€ , but have so far fallen 0% to 54.56€. Some other companies are on our watchlist to, among these are Deutsche Börse Aktiengesellschaft FRA:DB1 BP p.l.c. FRA:BPE5 and Nordex SE FRA:NDX1 which all got a breakout pattern emerging.
| Date | Company | Price | Week 23 |
|---|---|---|---|
| Rwe Aktiengesellschaft | 54.56€ | 56.00€ | 2.64% |
| Deutsche Börse Aktiengesellschaft | 247.60€ | 245.90€ | -0.687% |
| Bp P.l.c. | 5.99€ | 6.27€ | 4.60% |
| Nordex Se | 41.40€ | 40.82€ | -1.40% |
The RWE Aktiengesellschaft stock price gained 0.147% on the last trading day (Friday, 29th May 2026), rising from 54.48€ to 54.56€. During the last trading day the stock fluctuated 1.36% from a day low at 54.28€ to a day high of 55.02€. The price has been going up and down for this period, and there has been a -1.16% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 5 million more shares were traded than the day before. In total, 7 million shares were bought and sold for approximately 383.37€ million.
RWE Aktiengesellschaft holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About RWE Aktiengesellschaft:
RWE Aktiengesellschaft generates and supplies electricity from renewable and conventional sources primarily in Europe and the United States. It operates through five segments: Offshore Wind; Onshore Wind/Solar; Hydro/Biomass/Gas; Supply & Trading; and Coal/Nuclear. The company generates wind, solar, hydro, nuclear, gas, and biomass electricity. It also trades in energy commodities; and operates gas storage facilities, as well as battery storage activities. The company serves commercial, industrial, and corporate customers. RWE Aktiengesellschaft was founded in 1898 and is headquartered in Essen, Germany.
The Deutsche Börse Aktiengesellschaft stock price fell by -0.242% on the last day (Friday, 29th May 2026) from 248.20€ to 247.60€. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 1.63% from a day low at 245.40€ to a day high of 249.40€. The price has fallen in 6 of the last 10 days but is still up by 1.31% over the past 2 weeks. Volume has increased on the last day by 489 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 838 thousand shares were bought and sold for approximately 207.38€ million.
Deutsche Börse Aktiengesellschaft holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Deutsche Börse Aktiengesellschaft:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
The BP p.l.c. stock price gained 0.99% on the last trading day (Friday, 29th May 2026), rising from 5.94€ to 5.99€. During the last trading day the stock fluctuated 1.83% from a day low at 5.90€ to a day high of 6.01€. The price has fallen in 7 of the last 10 days and is down by -5.32% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 873 more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately 9.33€ million.
The BP p.l.c. stock holds several negative signals and despite the positive trend, we believe BP p.l.c. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
About BP p.l.c.:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
The Nordex SE stock price fell by -1.00% on the last day (Friday, 29th May 2026) from 41.82€ to 41.40€. During the last trading day the stock fluctuated 2.68% from a day low at 41.06€ to a day high of 42.16€. The price has fallen in 6 of the last 10 days and is down by -8.57% for this period. Volume has increased on the last day by 257 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 776 thousand shares were bought and sold for approximately 32.14€ million.
The Nordex SE stock holds several negative signals and despite the positive trend, we believe Nordex SE will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
About Nordex SE:
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
NESR
$25.06
|
0.439% | Jun 22 |
IDYA
$28.98
|
25.19% | Jun 12 |
PHM
$118.49
|
14.53% | Jun 10 |
DHI
$146.71
|
13.50% | Jun 10 |
EAT
$140.46
|
20.94% | Jun 05 |
